For several different tumors such as breast (13), colon (14), ovarian (15), endometrial (16), cervical (33), bladder (34), thyroid (35), gastric (36), esophageal (37), and gallbladder (38) cancers, a strong association between an increased expression of VEGF-D and the presence of lymph node metastases has already been demonstrated by IHC (13–16, 33) or at serum level (34–38); however, investigations on this biomarker regarding VSCC are lacking. Here, VEGFD is linked to cancer.